Switch theme
Sign up to access all valuation multiples
Shenzhen Mindray Bio-Medical Electronics Co Ltd is a developer, manufacturer, and supplier of medical devices. The company is focused on the medical industry in the fields of Patient Monitoring & Life Support, InVitro Diagnostics, and Medical Imaging.
1999
n/a
LTM Revenue $5.4B
LTM EBITDA $2.1B
$40.5B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Mindray has a last 12-month revenue of $5.4B and a last 12-month EBITDA of $2.1B.
In the most recent fiscal year, Mindray achieved revenue of $4.8B and an EBITDA of $1.9B.
Mindray expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Mindray valuation multiples based on analyst estimates| FY 2022 | FY 2023 | FY 2024 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $4.2B | $4.8B | $5.2B | $5.4B | XXX |
| Gross Profit | $2.3B | $2.7B | $3.2B | XXX | XXX |
| Gross Margin | 54% | 56% | 61% | XXX | XXX |
| EBITDA | $1.6B | $1.9B | $2.0B | $2.1B | XXX |
| EBITDA Margin | 39% | 40% | 39% | 39% | XXX |
| Net Profit | $1.1B | $1.3B | $1.6B | XXX | XXX |
| Net Margin | 26% | 28% | 30% | XXX | XXX |
| Net Debt | n/a | n/a | n/a | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of February 21, 2025, Mindray's stock price is CNY 258 (or $35).
Mindray has current market cap of CNY 313B (or $42.9B), and EV of CNY 295B (or $40.5B).
See Mindray trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $40.5B | $42.9B | XXX | XXX | XXX | XXX | $1.49 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of February 21, 2025, Mindray has market cap of $42.9B and EV of $40.5B.
Mindray's trades at 7.5x LTM EV/Revenue multiple, and 19.6x LTM EBITDA.
Analysts estimate Mindray's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Mindray and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $40.5B | XXX | XXX | XXX |
| EV/Revenue | 7.7x | XXX | XXX | XXX |
| EV/EBITDA | 20.1x | XXX | XXX | XXX |
| P/E | 24.3x | XXX | XXX | XXX |
| P/E/Growth | 1.4x | XXX | XXX | XXX |
| EV/FCF | 26.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpMindray's NTM/LTM revenue growth is 17%
Mindray's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.
Over next 12 months, Mindray's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Mindray's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Mindray and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 9% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 39% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 5% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 55% | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | n/a | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 5% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 1% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 10% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 29% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Electromed | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Mindray acquired XXX companies to date.
Last acquisition by Mindray was XXXXXXXX, XXXXX XXXXX XXXXXX . Mindray acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Mindray founded? | Mindray was founded in 1999. |
| Where is Mindray headquartered? | Mindray is headquartered in China. |
| Is Mindray publicy listed? | Yes, Mindray is a public company listed on SHE. |
| What is the stock symbol of Mindray? | Mindray trades under 300760 ticker. |
| When did Mindray go public? | Mindray went public in 2018. |
| Who are competitors of Mindray? | Similar companies to Mindray include e.g. Philips, Perspective Therapeutics, Electromed, InfuSystem. |
| What is the current market cap of Mindray? | Mindray's current market cap is $42.9B |
| What is the current revenue of Mindray? | Mindray's last 12-month revenue is $5.4B. |
| What is the current EBITDA of Mindray? | Mindray's last 12-month EBITDA is $2.1B. |
| What is the current EV/Revenue multiple of Mindray? | Current revenue multiple of Mindray is 7.5x. |
| What is the current EV/EBITDA multiple of Mindray? | Current EBITDA multiple of Mindray is 19.6x. |
| What is the current revenue growth of Mindray? | Mindray revenue growth between 2023 and 2024 was 9%. |
| Is Mindray profitable? | Yes, Mindray is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
